Bellevue Life Sciences Acquisition
BLAC | NASDAQ
$3.01
-$3.72 (-55.27%)
At close: Feb 14, 2025, 04:00 PM ET
Bellevue Life Sciences Acquisition Company Profile
Company profile explainedCompany Profile
Bellevue Life Sciences Acquisition Corp. currently does not engage in substantial operational activities. Its core mission is to orchestrate a business combination, which could manifest as a merger, share exchange, asset acquisition, stock purchase, recapitalization, or reorganization, with one or more enterprises or organizations within the healthcare domain. This firm, established in 2020, maintains its principal office in Bellevue, Washington, and operates as a subordinate entity of Bellevue Global Life Sciences Investors LLC.
Key Executives
| Name | Position |
|---|---|
| Kuk Hyoun Hwang | Chief Executive Officer & Executive Chairman |
| David Jin Yoo | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 17, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 8-K | Current Report |
| Jul 16, 2026 | DEF 14A | Filing |
Bellevue Life Sciences Acquisition
| Country | United States |
| IPO Date | Mar 21, 2023 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Kuk Hyoun Hwang |
Contact Details
10900 NE 4th Street Bellevue,
Washington 98004 United States
Stock Details
| Ticker Symbol | BLAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840425 |
| CUSIP Number | 68840D102 |
| ISIN Number | US68840D1028 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove BLAC